# Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

> **NCT01604122** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)
- Transthyretin Cardiomyopathy (TTR-CM)
- Familial Amyloid Cardiomyopathy
- Senile Systemic Amyloidosis (SSA)

## Interventions

- **OTHER:** No drug
- **OTHER:** No drug

## Key facts

- **NCT ID:** NCT01604122
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-18
- **Primary completion:** 2015-07-27
- **Final completion:** 2016-07-18
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01604122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01604122, "Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01604122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*